# IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

> **NCT01234974** · PHASE2 · WITHDRAWN · sponsor: **Milton S. Hershey Medical Center**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pasireotide
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01234974
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2013-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never undertaken
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01234974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01234974, "IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01234974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*